Role of HBV genotype in predicting response to lamivudine therapy in patients with chronic hepatitis B

Indian Journal of Gastroenterology

Volumn 24, Issue 1, 2005, Pages 12-15

  Thakur, V ^a   Sarin, S K ^a   Rehman, S ^a   Guptan, R C ^a   Kazim, S N ^a   Kumar, S ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEROCONVERSION; VIRUS DETECTION; VIRUS GENE;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 15044357403     PISSN: 02548860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Chien RN, Liaw YF, Alkins M. Pretherapy alanine transaminase levels as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999;30:770-4.
2. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-94.
3. Lai CL, Chein RN, Leung NW, Chang TT, Guan R, Tai DI. A one-year trial of lamuvidine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339: 61-8.
4. Perez V, Tanno H, Villamil F, Fay O. Recombinant interferon alpha-2b following prednisone withdrawal in the treatment of chronic type B hepatitis. J Hepatol 1990;11:S113-S117.
5. Perrilo RP, Schiff ER, Davis GL, Bodenheimer HC Jr., Lindsay K, Payne J. A randomized control trial of interferon alpha 2b alone and after prednisolone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
6. Kao JH, Chen PJ, Lai MY, Yang PM, Shen JC, Wang TH, et al. Genotypes of hepatitis C virus in Taiwan and the progression of liver disease. J Clin Gastroenterol 1995;21: 233-7.
7. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotypes are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 1995;22:1050-6.
8. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an a la carte combination interferon alpha 2 b plus ribavirin regimen possible for the first time treatment in patients with chronic hepatitis C? The AlGOVIR C project group. Hepatology 2000;31:211-8.
9. Norder H, Courouce AM, Magnius LO. Complete genome, phylogenetic relatedness and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994;198:489-503.
10. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, et al. A new genotype of hepatitis B virus. Complete genome and phylogenetic relatedness. J Gen Virol 2000;81:67-74.
11. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Ameri-Indian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002;83:2059-73.
12. Okamoto H, Tsuda F, Sakagawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, et al. Typing hepatitis B virus by homology in nucleotide sequence comparison of surface antigen subtypes. J Gen Virol 1988;69:2575-83.
13. Norder H, Hammas B, Lee SD, Bele C, Courouce AM, Mushawar IK, et al. Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variation in the primary structure of the surface gene. J Gen Virol 1993;74:1341-8.
14. Arankalle VA, Murhekar KM, Gandhe SS, Murhekar MV, Ramdasi AY, Padbidri VS, et al. Hepatitis B virus: predominance of genotype D in primitive tribes of the Andaman and Nicobar islands, India (1989-1999). J Gen Virol 2003; 84:1915-20.
15. Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK. Profile, spectrum and significance of HBV genotype in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol 2002;17:165-70.
16. Erhardt A, Reineke V, Blondin D, Gerlich WH, Adams O, Heintges T, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000;31:716-25.
17. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotype and the response to interferon therapy. J Hepatol 2000;33:998-1002.
18. Zhang X, Zoulium F, Habersetzer F, Xiong S, Trepo C. Analysis of hepatitis B virus genotypes and precore region variability during interferon treatment of HBeAg negative chronic hepatitis B. J Med Virol 1996;48:8-16.
19. Kao JH, Liu CJ, Chen DS. Hepatitis B virus genotypes and lamivudine resistance. J Hepatol 2002;36:303-4.
20. Buti M, Cotrina M, Valdes A, Jardi R, Prias FR, Esteban R. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? J Hepatol 2002;36:445-6.
21. Knodell RG, Ishak KG, Black WC, Chen TC, Craig R, Koplowitz N, et al. Formulation and application of a mathematical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
22. Lindh M, Gonzalez JE, Narkrans G, Moral P. Genotyping of hepatitis B virus by restriction pattern analysis of a pre-S amplicon. J Virol Meth 1998;72:163-74.
23. Zollner B, Peterson J, Schafer P, Schroter M, Laufs R, Sterneck M, et al. Subtype dependent response of hepatitis B virus during the early phase of lamivudine therapy. Clin Infect Dis 2002;34:1273-7.
24. Chien RN, Liaw YF, Atkino M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asia Hepatitis Lamivudine Trial Group. Hepatology 1999;30:770-4.
25. Lee KM, Cho SW, Kim SW, Kim HJ, Lalm, Kin JH. Effect of virological response on post treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepatitis 2002;9:208-12.
26. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-6.
27. Lee CM, Ong GY, Lu SN, Wang JH, Liao CA, Tung HD, et al. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol 2002;37:669-74.
28. Hong SP, Han KH, Ahn SH, Paik YH, Chon CY, Moon YM. Additional lamivudine therapy after HBeAg seroconversion would prolong the durability of response in HBV endemic area (Abstract). Hepatology 2001;34:322A.
29. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-94.